# Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

> **NCT00220389** · PHASE2 · COMPLETED · sponsor: **Pfizer**

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** SPM 907

## Key facts

- **NCT ID:** NCT00220389
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** — (—)
- **Last updated:** 2008-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00220389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00220389, "Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00220389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*